Referenties
1Duarte RV, Raphael JH, Sparkes E, Southall JL, LeMarchand K, Ashford RL. Long-term intrathecal drug administration for chronic nonmalignant pain. J Neurosurg Anesthesiol. 2012;24:63-70.
2Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of lowdose intrathecalopioids in the management of chronic nonmalignant pain. Pain Med. 2012;13(10):1304-1313.
3Deer T, Chapple I, Classen A, et aI. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. Pain Med. 2004;5(1):6-13.
4Ellis DJ, Dissanayake S, McGuire D, et al. Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. Neuromodulation. 2008;11:40-49.
5Atli A, Theodore BR, Turk DC, Loeser JD. Intrathecalopioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. Pain Med. 2010;11(7):1010-1016.
6Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040-4049.
7Roberts U, Finch PM, Goucke CR, Price LM. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001;5(4):353-361.
8Winkelmuller M, Winkelmuller W. Long-term effects of continuous intrathecalopioid treatment in chronic pain of nonmalignant etiology. J Neurosurg.1996;85(3):458-467.
9Brogan E, Winter NB, Okifuji A. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. Reg Anesth Pain Med. 2015;40(4):369–75.
10Smith TJ, Coyne PJ. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med. 2005;8(4):736–42.
11Syed Rizvi & Krishna Kumar. History and Present State of Targeted Intrathecal Drug Delivery. Curr Pain Headache Rep (2015) 19:1 DOI 10.1007/s11916-014-0474-8.
12Brogan SE, Sindt JE, et al. Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy. Anesth Analg. 2019 Jun 12. doi: 10.1213/ANE.0000000000004276. [Epub ahead of print]
13Stearns LM, Abd-Elsayed A, Perruchoud C, et al. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry. Anesth Analg. 2020;130(2):289-297
14Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10:357-366.